Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies
- 1 November 2005
- journal article
- phase i-and-clinical-pharmacology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (31), 7785-7793
- https://doi.org/10.1200/jco.2004.00.6148
Abstract
Purpose ABI-007 is a novel solvent-free, albumin-bound, 130-nm particle formulation of paclitaxel designed to avoid solvent-related toxicities and to deliver paclitaxel to tumors via molecular path...Keywords
This publication has 33 references indexed in Scilit:
- Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)Clinical Cancer Research, 2005
- Cytosine Β-D Arabino-Furanoside (Ara-C) and CPT-11 inhibit cell proliferation in human colorectal cancer with microsatellite instabilityJournal of Clinical Oncology, 2004
- Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimensBritish Journal of Cancer, 2004
- Pharmacological Effects of Formulation VehiclesClinical Pharmacokinetics, 2003
- Cremophor ELEuropean Journal Of Cancer, 2001
- The taxanes: an updateThe Lancet, 2000
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Taxol: A Novel Investigational Antimicrotubule AgentJNCI Journal of the National Cancer Institute, 1990
- Hypersensitivity reactions from taxol.Journal of Clinical Oncology, 1990
- Promotion of microtubule assembly in vitro by taxolNature, 1979